Aging (Albany NY) . Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19

[tetano]

Aging (Albany NY)


. 2020 Aug 14;12.
doi: 10.18632/aging.103770. Online ahead of print.
Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19


Chang Li ¹ , Jianfang Ye ^{2 3} , Qijian Chen ⁴ , Weihua Hu ⁵ , Lingling Wang ^{2 3} , Yameng Fan ⁶ , Zhanjin Lu ^{2 3} , Jie Chen ⁷ , Zaishu Chen ⁸ , Shiyan Chen ^{2 3} , Junlu Tong ^{2 3} , Wei Xiao ¹ , Jin Mei ⁹ , Hongyun Lu ¹⁰



Affiliations

• PMID: 32805722
• DOI: 10.18632/aging.103770

Abstract

Early identification of severe patients with coronavirus disease 2019 (COVID-19) is very important for individual treatment. We included 203 patients with COVID-19 by propensity score matching in this retrospective, case-control study. The effects of serum lactate dehydrogenase (LDH) at admission on patients with COVID-19 were evaluated. We found that serum LDH levels had a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 U/L, for predicting severe COVID-19. And a cut-off of 359.50 U/L of the serum LDH levels resulted in a 93.8% sensitivity, 88.2% specificity for predicting death of COVID-19. Additionally, logistic regression analysis and Cox proportional hazards model respectively indicated that elevated LDH level was an independent risk factor for the severity (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) and mortality (HR: 40.50, 95% CI: 3.65-449.28; P=0.003) of COVID-19. Therefore, elevated LDH level at admission is an independent risk factor for the severity and mortality of COVID-19. LDH can assist in the early evaluating of COVID-19. Clinicians should pay attention to the serum LDH level at admission for patients with COVID-19.

Keywords: COVID-19; lactate dehydrogenase; mortality; risk factor; severity.